Do Statins Cause Frequent Urination?

Statins have not been convincingly shown to cause frequent urination in controlled clinical trials, but the question is far from settled. Adverse event databases do contain a statistical signal linking statins to urinary storage symptoms like frequent urination and nighttime urination, and at least one large randomized trial recorded a small excess of renal and urinary side effects in the statin group. Yet when researchers have tried to pin down a direct cause-and-effect relationship, confounding factors and the nocebo effect keep muddying the picture. The biology is surprisingly contradictory too, with some laboratory evidence suggesting statins should reduce urine output rather than increase it.

What Adverse Event Reports Actually Show

The most direct look at this question comes from mining the FDA’s adverse event reporting system. A study analyzing voluntary reports to the FDA found statistically elevated reporting odds for both “voiding” symptoms (things like weak urine stream and painful urination) and “storage” symptoms (frequent urination and nighttime urination) among statin users. The storage-symptom signal was slightly stronger, with frequent urination and nocturia driving that category. Not all statins showed the same pattern: simvastatin, rosuvastatin, pravastatin, atorvastatin, pitavastatin, and lovastatin each showed up for storage symptoms, while a smaller subset flagged for voiding problems.¹

There is also clinical trial evidence pointing in the same direction. The large Anglo-Scandinavian Cardiac Outcomes Trial recorded a modest but statistically significant excess of renal and urinary adverse events among patients randomized to atorvastatin compared with placebo, roughly 1.9% per year versus 1.5% per year.² That difference is real, but it lumps together everything from kidney-related lab abnormalities to urinary symptoms, so it does not tell you how much of that excess was specifically about needing to urinate more often.

Adverse event reports are useful as early warning signals, but they have a well-known limitation: the people who file them are already suspecting the drug. Someone who started a statin and then noticed more trips to the bathroom is more likely to report it than someone whose urinary habits stayed the same. That asymmetry inflates signals, sometimes dramatically.

The Confounding Problem

People who take statins tend to be older, more likely to have high blood pressure, more likely to have diabetes, and more likely to be seeing a doctor regularly. Every one of those factors independently raises the odds of urinary symptoms. So the question becomes: are statins actually doing something to the urinary tract, or are statin users just the kind of people who develop urinary issues anyway?

A prospective study of older men tackled this head-on. At first glance, statin users appeared more likely to develop lower urinary tract symptoms. But when the researchers restricted their comparison to men who were also taking blood pressure medications, using that as a rough proxy for similar levels of medical engagement, the association vanished. The hazard ratio for new urinary symptoms dropped to essentially 1.0, and the hazard ratio for symptom progression did the same.³ The researchers concluded that confounding, not the drug itself, was the likely explanation for the apparent link.

There is also the nocebo effect to consider. When people expect a medication to cause side effects, they tend to experience those side effects regardless of whether the drug is actually responsible. The SAMSON trial, a cleverly designed crossover study where patients cycled through periods on a statin, on a placebo pill, and on no pill at all, found that symptom scores were much worse on any tablet compared with taking nothing, but no different between the statin tablet and the placebo tablet. The expectation of side effects, not the drug’s pharmacology, was the dominant driver of reported symptoms.⁴ That trial measured general symptom burden rather than urinary symptoms specifically, but the principle applies broadly: if you read the package insert and then start paying attention to your bathroom visits, you may notice patterns that were already there.

Statins and the Prostate

In men, the prostate gland wraps around the urethra, and an enlarged prostate is one of the most common reasons older men deal with frequent urination, a weak stream, or the sensation of not fully emptying the bladder. Since statins are overwhelmingly prescribed to the same age group that develops prostate enlargement, the overlap between statin use and urinary symptoms in men has a built-in demographic explanation. But some researchers have gone further and asked whether statins might actually help prostate-related urinary symptoms rather than worsen them.

A meta-analysis pooling results from multiple studies found that statins appeared to slow the progression of lower urinary tract symptoms in patients with high cholesterol. The effect was modest but statistically significant, and it was more pronounced when statin use lasted longer than one year.⁵ Separately, one study found that statin treatment reduced prostate volume and prostate-specific antigen levels in men with benign prostatic enlargement, a finding the authors interpreted as potentially beneficial for urinary symptoms.⁶

However, when a randomized placebo-controlled trial directly tested whether atorvastatin improved urinary symptoms in men with prostate enlargement, it found no difference whatsoever. The symptom score improvement was nearly identical between the statin and placebo groups after six months, and secondary measures like prostate volume and peak urine flow rate also showed no separation.⁷ So the picture in men is a muddle. Observational data hints at possible benefit, but the most rigorous test of the idea came up empty.

What Statins Do to the Bladder

The bladder itself is another place where statins could theoretically influence urinary frequency, and here the evidence pulls in opposing directions depending on the context.

In animal models of overactive bladder caused by poor blood flow, statins have shown a protective effect. A rat study found that statin treatment improved bladder blood flow, reduced inflammation, and calmed the overactive contractions that drive urgency and frequency.⁸ Another animal experiment showed that simvastatin reversed the abnormal bladder contractions and inflammation caused by a chemical irritant, essentially normalizing bladder function.⁹ In these laboratory settings, statins look like they would reduce urinary frequency, not increase it.

But there is a darker possibility. A population-based case-control study found that statin use was associated with a roughly 50% higher odds of being diagnosed with bladder pain syndrome, also known as interstitial cystitis, a chronic condition whose hallmark symptoms include urinary urgency, frequency, and pelvic pain. The association held after adjusting for a long list of potential confounders including diabetes, hypertension, and irritable bowel syndrome. The authors speculated that statins might damage the bladder’s protective lining, since the cholesterol pathways statins disrupt are involved in maintaining cell membranes throughout the body, including the urothelium.¹⁰ If your frequent urination comes with bladder discomfort or a burning sensation, that association could be relevant, though one observational study is not enough to establish causation.

At the extreme end, there is at least one published case report of a woman who developed urinary retention, the opposite of frequent urination, after starting a statin. The bladder muscle itself seemed damaged, and even after the drug was stopped, only modest improvement followed.¹¹ This is a single case and not something to lose sleep over, but it underscores that statins can potentially affect bladder muscle function in unpredictable ways, both overactivity and underactivity have been described.

Statins and Water Balance in the Kidneys

Here is where the story gets genuinely surprising. If statins affected the kidneys in a way that produced more urine, that would be a clean explanation for frequent urination. But the laboratory evidence points in the opposite direction.

Statins have been found to increase the expression and trafficking of a water channel called aquaporin-2 in the kidneys. This channel is the main valve the body uses to pull water back out of urine and return it to the bloodstream. More aquaporin-2 at the cell surface means more water reabsorption, which means more concentrated urine and less of it. A study in patients with high cholesterol confirmed this in humans: simvastatin increased aquaporin-2 levels in the urine, reduced total daily urine volume, and made urine more concentrated.¹² This effect has attracted interest as a potential treatment for nephrogenic diabetes insipidus, a rare condition where the kidneys cannot concentrate urine properly and patients produce enormous volumes of dilute urine.¹³

A separate study looking at atorvastatin’s effects on kidney function in patients with chronic kidney disease found changes in certain sodium channel markers but no meaningful change in overall sodium excretion or urine water handling at the whole-body level.¹⁴ So statins do interact with kidney physiology, but the net effect on urine volume, to the extent it exists, seems to go in the direction of less output rather than more.

This is where the puzzle sharpens. If statins reduce urine volume through the kidney, they should not cause frequent urination on that basis alone. Any urinary frequency linked to statins would more likely originate from the bladder, the prostate, or the nervous system governing bladder sensation, rather than from producing extra urine.

Why Sorting This Out Is So Difficult

The frustrating reality is that urinary frequency has dozens of causes, and the population that takes statins is the same population most prone to those causes. Age-related bladder changes, prostate enlargement, diabetes-related nerve damage, blood pressure medications that act as diuretics, caffeine intake, and plain old fluid habits all contribute. Isolating the contribution of one drug against that noisy background is a methodological nightmare.

The evidence splits into two rough camps. Adverse event databases and at least one randomized trial suggest a small, real excess of urinary-tract complaints among statin users. But when researchers have tried to control for the many confounders, the signal tends to weaken or disappear. And the biological evidence from the kidney actually suggests statins would reduce urine production, not increase it. The bladder-level evidence is mixed, with animal studies showing protective anti-inflammatory effects in some models but a possible association with bladder pain syndrome in one human observational study.

For any individual person, the most practical approach is pattern recognition. If you started a statin and noticed a clear change in urinary frequency within weeks, it is worth mentioning to your doctor. Switching to a different statin or adjusting the dose is straightforward. But if you have been on a statin for years and are now experiencing urinary symptoms, age-related causes are statistically far more likely, and a urological evaluation will be more productive than stopping a medication that is protecting your cardiovascular system.

Statins and Bladder Pain Syndrome

Frequent urination is not always about volume. In bladder pain syndrome, also called interstitial cystitis, the bladder’s inner lining becomes irritated or damaged, and the brain misinterprets normal bladder filling as urgent. The result is the constant feeling that you need to urinate even when the bladder is not full. Trips to the bathroom become frequent but produce little urine each time, and there is often pain or discomfort in the pelvic area.

The population-based study mentioned earlier found that statin users had about 50% higher odds of being diagnosed with this condition compared with non-users. The proposed mechanism is that statins, by disrupting cholesterol synthesis in cell membranes, could compromise the bladder’s glycosaminoglycan layer, the mucus-like coating that shields the underlying tissue from the irritants in urine.¹⁰ This is biologically plausible: cholesterol is a structural component of every cell membrane, and the bladder lining is one of the most metabolically active epithelial surfaces in the body. But plausible is not the same as proven, and the finding has not been replicated in a large prospective trial.

If your urinary frequency is accompanied by pelvic pressure, pain during bladder filling, or discomfort that worsens with certain foods and drinks, a conversation with a urologist is more useful than adjusting statin therapy on your own. Bladder pain syndrome has its own diagnostic pathway and treatment options, and even if a statin contributed to its onset, stopping the statin alone may not resolve the symptoms.

Which Statins Are More Likely to Be Involved

The FDA adverse event data did not show a uniform signal across all statins. For storage symptoms like frequent urination and nighttime urination, the broadest signal appeared with simvastatin, rosuvastatin, pravastatin, atorvastatin, pitavastatin, and lovastatin. For voiding symptoms like weak stream and difficulty starting urination, the signal was narrower, showing up mainly with rosuvastatin, atorvastatin, and lovastatin.¹

Whether these differences reflect genuine pharmacological differences between statins or just prescription volume (atorvastatin and simvastatin are by far the most commonly prescribed, so they generate the most reports of everything) is unclear. Statins do differ in how they are metabolized and how easily they cross cell membranes, and it is conceivable that a lipid-soluble statin reaches bladder tissue more readily than a water-soluble one. But that kind of tissue-level pharmacokinetic work has not been done for the bladder. If you and your doctor suspect a statin is contributing to urinary symptoms, switching to a different statin within the class is a reasonable first step before considering stopping altogether.

When Statin Benefits Clearly Outweigh Urinary Complaints

Statins remain among the most extensively studied medications in the history of medicine, with strong evidence for reducing heart attacks, strokes, and cardiovascular death in people at elevated risk. Urinary frequency, while annoying, is not dangerous. The risk of stopping a statin because of a urinary symptom that may not even be caused by the drug is real: cardiovascular events are far more consequential than an extra trip to the bathroom at night.

That said, quality of life matters, and frequent urination or nocturia can seriously disrupt sleep and daily functioning. The reasonable path is not to dismiss the symptom or to reflexively blame the statin, but to methodically evaluate what is going on. A brief drug holiday supervised by your prescriber, with attention to whether symptoms actually change, can sometimes clarify the picture. If symptoms persist off the statin, the drug was not the cause. If they resolve and return upon restarting, you have useful information that can guide a switch to a different statin or a dose adjustment. This approach is more informative than relying on adverse event databases or internet forums, where confirmation bias runs strong and confounding runs stronger.